South Rampart Pharma is developing a new class of small molecule, non-opioid pain medicines. South Rampart Pharma’s (SRP) proprietary compounds have been effective in reducing both pain and fever in preclinical studies without liver and kidney toxicity that are associated with current common over the counter analgesics. SRP compounds are non-opioid, greatly reducing abuse potential.
South Rampart Pharma's Technology
Using extensive knowledge of drug metabolism, molecular modeling and medicinal chemistry, South Rampart Pharma’s synthesized novel compounds have a unique profile as demonstrated in preclinical models:
Additionally, South Rampart Pharma synthesized these new compounds using derivatives of the active metabolite of a first generation ApAP analgesic and all IND-enabling toxicology studies show a favorable safety profile.